Stifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00

Key Points

• Stifel Nicolaus raised its price target for Palvella Therapeutics (NASDAQ:PVLA) from $60.00 to $80.00, indicating a potential upside of 34.43% from its previous close.
• Palvella's stock has gained attention from several analysts, with ratings ranging from "buy" to "outperform," and a consensus average target price of $64.09.
• The company reported a loss of $0.86 earnings per share (EPS) for the last quarter, missing estimates, and has an anticipated EPS of -3.69 for the current fiscal year.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) had its target price hoisted by stock analysts at Stifel Nicolaus from $60.00 to $80.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Stifel Nicolaus' target price suggests a potential upside of 34.43% from the company's previous close.

PVLA has been the subject of several other reports. Chardan Capital increased their target price on Palvella Therapeutics from $50.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Oppenheimer began coverage on shares of Palvella Therapeutics in a research note on Tuesday, September 9th. They set an "outperform" rating and a $85.00 price objective on the stock. Raymond James Financial set a $54.00 target price on shares of Palvella Therapeutics and gave the stock an "outperform" rating in a research report on Tuesday, August 5th. HC Wainwright upped their target price on shares of Palvella Therapeutics from $38.00 to $75.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Finally, Lifesci Capital assumed coverage on Palvella Therapeutics in a research note on Monday, August 4th. They issued an "outperform" rating and a $90.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $64.09.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock traded up $2.82 during trading on Wednesday, hitting $59.51. The company's stock had a trading volume of 199,502 shares, compared to its average volume of 103,240. Palvella Therapeutics has a 1-year low of $11.17 and a 1-year high of $63.12. The stock's fifty day moving average is $47.04 and its 200 day moving average is $32.22. The stock has a market capitalization of $658.18 million, a price-to-earnings ratio of -4.92 and a beta of -0.03.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, research analysts anticipate that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PVLA. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics in the 2nd quarter worth approximately $37,000. Spire Wealth Management bought a new stake in shares of Palvella Therapeutics during the first quarter valued at about $70,000. JPMorgan Chase & Co. lifted its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after purchasing an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Palvella Therapeutics in the 2nd quarter valued at about $85,000. Finally, BNP Paribas Financial Markets acquired a new position in Palvella Therapeutics during the 2nd quarter valued at about $104,000. Institutional investors and hedge funds own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.